Mesoblast is working on a new treatment for stroke, spinal cord injuries, and Parkinson's and Huntington's diseases that involves the use of dental pulp stem cells.
These stem cells are especially valuable because they are a type of mesenchymal stem cell known to produce more neurotrophic factors than other adult stem cell types, according to the company.
The dental pulp stem cells are STRO-1-positive, meaning they tend to be more homogenous and have higher rates of adherence and proliferation than other mesenchymal progenitor cells (MPCs), according to the company. STRO-1 is a monoclonal antibody used in the sorting and identification of MPCs, making them ideal candidates for regenerative treatments.
